46
total announcements
MANKIND.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹93,067 Cr
P/E (TTM)
45.6
P/E (Forward)
31.8
EPS (TTM)
₹49.42
52W Low
₹1,909.70
52W High
₹2,642.00
Dividend Yield
0.00%
Beta
0.45
Price / Book
5.7
Debt / Equity
38.1
Revenue (TTM)
₹14,738 Cr
Gross Margin
70.76%
Operating Margin
20.61%
Mankind Pharma Limited
Mankind Pharma Limited has received an ESG rating of '71' from NSE Sustainability, a SEBI registered ESG Rating Provider, for FY26, based on publicly available information.
Mankind Pharma Limited
Mankind Pharma Limited has announced that its Board of Directors has approved the acquisition of a majority stake (70%) in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company, through its wholly-owned subsidiary Mankind Pharma (Netherlands) B.V. The acquisition is part of the Company's long-term strategy to build a global innovation-led pharmaceutical business.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about Acquisition of majority stake (70%) in Armed Cell Therapeutics B.V. (ACTx) through its wholly-owned subsidiary Mankind Pharma (Netherlands) B.V. for EUR 48Mn in installments.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 15, 2026. The Board of Directors has considered and approved an additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V. and the acquisition of a majority stake (i.e., 70%) in Armed Cell Therapeutics B.V. through Mankind Netherlands.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about the schedule of an earnings conference call to discuss the business and financial results of the Company for Q2 & H1 FY27 on October 26, 2026.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialisation/rematerialisation of shares for the quarter ended September 30, 2026.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about the resignation of its statutory auditor.
Mankind Pharma Limited
Mankind Pharma Limited has announced the resignation of the statutory auditors of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited, due to the initiation of voluntary liquidation proceedings under the Insolvency and Bankruptcy Code, 2016.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Mankind Pharma Limited
Mankind Pharma Limited has submitted the Exchange a copy of the Scrutinizer's report of the Postal Ballot. The company has informed the Exchange regarding voting results for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The resolution was passed with the requisite majority.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about its ESG Rating, which was assigned by Niche99 ESG Ratings as 68.21 under the 'Leader' category for FY 2025-26.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about the schedule of a meet.
Mankind Pharma Limited
Mankind Pharma Limited has informed about the approval of its wholly owned subsidiary Bharat Serums and Vaccines Limited's members for voluntary liquidation, subject to creditor approval.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange regarding the allotment of 49,112 shares under the Mankind Employee Stock Option Plan 2022 to eligible employees.
Mankind Pharma Limited
Mankind Pharma Limited has completed the sale of its 100% stake in Broadway Hospitality Services Private Limited to AKRK Projects LLP and its Partners, effective August 31, 2026.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange regarding the cessation of Mr. Bharat Anand as a Non-Executive Independent Director of the company, effective August 30, 2026.
Mankind Pharma Limited
Mankind Pharma Limited has announced the integration of its wholly owned subsidiary Bharat Serums and Vaccines Limited (BSVL) into the company through voluntary liquidation. The business of BSVL will be distributed to Mankind Pharma on a going concern basis, and Appian, a wholly owned subsidiary of Mankind Pharma, will receive cash proportionate to its shareholding in BSVL.
Mankind Pharma Limited
Mankind Pharma Limited has announced the outcome of its Board Meeting, where it has consented to the integration of Bharat Serums and Vaccines Limited, a wholly owned material subsidiary, into the Company by way of voluntary liquidation. The business of BSVL will be distributed to the Company on a going concern basis, and Appian, a wholly owned subsidiary of the Company, will receive cash proportionate to its shareholding.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about General Updates, specifically an improvement in Environmental, Social and Governance (ESG) Rating from 57 to 64, classified under the 'Strong' category, and an improvement in Core ESG Rating from 60 to 71.
Mankind Pharma Limited
Mankind Pharma Limited has entered into an exclusive in-licensing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialization of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India. This partnership further strengthens Mankind Pharma's presence in the diabetes segment and expands its portfolio of advanced injectable therapies.